If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

Merck (NYSE:MRK) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

Japan’s retail sales and job data fuel BoJ rate hike bets, pressuring USD/JPY. Fed’s inflation stance also in focus. Will USD ...

The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

ASML’s earnings boost EURO STOXX 50, offsetting weak German confidence data. EUR/USD awaits key breakout levels. Full ...

The immediate resistance level emerges at the 1.5095–1.5100 region; the first downside target is seen at 1.4936.